TuHURA Biosciences, Inc. (NASDAQ:HURA) has reported financial results for the second quarter ending June 30, 2025. The company recorded research and development expenses amounting to $4.9 million, a significant increase from the $2.8 million recorded in the same period in 2024. Net cash outflows from operating activities were reported at $10.9 million for the six months ending June 30, 2025, compared to $8.9 million for the same period in 2024. Additionally, TuHURA completed a $12.5 million equity financing transaction and received $3 million from warrant exercise proceeds. In terms of corporate developments, TuHURA has been included in the Russell 3000® and Russell 2000® Indexes as of June 27, 2025. Furthermore, the company completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody, now named "TBS-2025." Plans are underway to initiate a Phase 2 trial of TBS-2025 in combination with a menin inhibitor for the treatment of relapsed or refractory NPM1-mutated Acute Myeloid Leukemia $(AML.AU)$ in the second half of 2025. TuHURA has also initiated a Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® for advanced and metastatic Merkel cell carcinoma (MCC).